Literature DB >> 16157735

Pharmacotherapy--add-on therapies.

.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 16157735      PMCID： PMC1329952     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  17 in total

1.  Salmeterol in paediatric asthma.

Authors:  C Byrnes; S Shrewsbury; P J Barnes; A Bush
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

2.  What is new since the last (1999) Canadian Asthma Consensus Guidelines?

Authors:  L P Boulet; T R Bai; A Becker; D Bérubé; R Beveridge; D M Bowie; K R Chapman; J Côté; D Cockcroft; F M Ducharme; P Ernst; J M FitzGerald; T Kovesi; R V Hodder; P O'Byrne; B Rowe; M R Sears; F E Simons; S Spier
Journal:  Can Respir J       Date:  2001 Mar-Apr       Impact factor: 2.409

Review 3.  Presentation of new GINA guidelines for paediatrics. The Global Initiative on Asthma.

Authors:  E Von Mutius
Journal:  Clin Exp Allergy       Date:  2000-06       Impact factor: 5.018

4.  Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma.

Authors:  N J Van den Berg; M S Ossip; C A Hederos; H Anttila; B L Ribeiro; P I Davies
Journal:  Pediatr Pulmonol       Date:  2000-08

5.  Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.

Authors:  B Knorr; L M Franchi; H Bisgaard; J H Vermeulen; P LeSouef; N Santanello; T M Michele; T F Reiss; H H Nguyen; D L Bratton
Journal:  Pediatrics       Date:  2001-09       Impact factor: 7.124

6.  Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study.

Authors:  F E Simons; J R Villa; B W Lee; A M Teper; B Lyttle; G Aristizabal; W Laessig; A Schuster; J Perez-Frias; B E Sekerel; J Menten; J A Leff
Journal:  J Pediatr       Date:  2001-05       Impact factor: 4.406

7.  Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma.

Authors:  S F Weinstein; D S Pearlman; E A Bronsky; A Byrne; T Arledge; R Liddle; E Stahl
Journal:  Ann Allergy Asthma Immunol       Date:  1998-07       Impact factor: 6.347

8.  Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma.

Authors:  A Tal; G Simon; J H Vermeulen; V Petru; N Cobos; M L Everard; K de Boeck
Journal:  Pediatr Pulmonol       Date:  2002-11

9.  Salmeterol xinafoate in children on high dose inhaled steroids.

Authors:  G Russell; D A Williams; P Weller; J F Price
Journal:  Ann Allergy Asthma Immunol       Date:  1995-11       Impact factor: 6.347

10.  One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma.

Authors:  George Bensch; William E Berger; Boris M Blokhin; Aron L Socolovsky; Moira H Thomson; M Denise Till; Jordi Castellsague; Giovanni Della Cioppa
Journal:  Ann Allergy Asthma Immunol       Date:  2002-08       Impact factor: 6.347
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.